Results 151 to 160 of about 178,774 (332)

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. [PDF]

, 2019
Glioblastoma is the most common primary malignant brain tumor in adults and is associated with poor survival. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a randomized, multi-institution clinical trial to evaluate immune responses ...
Arrillaga-Romany, Isabel C, Butowski, Nicholas A, Clarke, Jennifer L, Cloughesy, Timothy F, Cohen, Adam L, Colman, Howard, Davidson, Tom B, de Groot, John F, Du, Lin, Ellingson, Benjamin M, Gaffey, Sarah C, Hugo, Willy, Kaley, Thomas J, Kawaguchi, Eric S, Lee, Alexander H, Lee, Eudocia Q, Li, Gang, Liau, Linda M, Mellinghoff, Ingo K, Mochizuki, Aaron Y, Nghiemphu, Phioanh L, O'Brien, Barbara J, Orpilla, Joey R, Prins, Robert M, Reardon, David A, Rytlewski, Julie A, Sanders, Catherine M, Wang, Anthony C, Wen, Patrick Y, Yong, William H   +29 more
core  

Artificial intelligence strategies for predicting kinase inhibitor resistance: A comprehensive review of methods, challenges, and future perspectives

Journal of Intelligent Medicine, EarlyView.
Abstract Kinase inhibitors are essential in targeted cancer therapy, yet resistance often emerges through secondary mutations, activation of compensatory signaling pathways, or drug‐efflux mechanisms. Artificial intelligence (AI) provides a workflow‐based strategy rather than a list of unrelated tools for predicting and addressing kinase‐inhibitor ...
Faris Hassan, Mohanad Ali Deifallah, Alaa Zaghloul, Rania Elgohary   +3 more
wiley   +1 more source

EP-1333: Re-recurrence pattern after re-irradiation with bevacizumab in recurrent malignant glioma

, 2015
Maximilian Niyazi, Natalie Jansen, M. Rottler, Ute Ganswindt, Claus Belka   +4 more
openalex   +1 more source

Clinical Outcomes of Different Generation EGFR TKIs in Susceptible EGFR‐Mutated Advanced Nonsmall‐Cell Lung Cancer

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are indicated for advanced lung adenocarcinoma patients harboring susceptible EGFR mutations. The aim of this retrospective study was to compare the effectiveness of different generations of EGFR TKIs.
Chia‐Yu Kuo, Tien‐Chi Huang, Chih‐Jen Yang, Mei‐Hsuan Lee, Jui‐Ying Lee, Ying‐Ming Tsai, Kuan‐Li Wu, Cheng‐Hao Chuang, Inn‐Wen Chong, Jen‐Yu Hung   +9 more
wiley   +1 more source

Efficacy and Safety of Bevacizumab in Combination with Carboplatin and Paclitaxel for Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer

, 2012
Kiyotaka Yoh, Kōichi Goto, Hironobu Ohmatsu, Seiji Niho, Shigeki Umemura, Yuichiro Ohe   +5 more
openalex   +1 more source

ACTR-61. A RANDOMIZED PHASE 2 TRIAL OF CEDIRANIB IN COMBINATION WITH OLAPARIB VERSUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA [PDF]

, 2019
Isabel Arrillaga‐Romany, Solmaz Sahebjam, David Picconi, Jian Campian, Pierre Giglio, Jan Drappatz, Robert Aiken, John L. Villano, Eudocia Q. Lee, Mary Welch, Benjamin M. Ellingson, Douglas Ney, Kevin Becker, Alona Muzikansky, Biswajit Das, Elizabeth M. Swisher, Andrew B. Nixon, Chris Karlovich, P. Mickey Williams, S. Percy Ivy, Tracy T. Batchelor, Elizabeth R. Gerstner   +21 more
openalex   +1 more source

Phase IIb Trial for the Palliative Treatment of Patients With Primary Hepatic Malignancy Unable to Receive Curative Treatment: Efficacy of Colchicine

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT This trial was to evaluate the efficacy and the safety of colchicine for the palliative treatment of patients with primary hepatic malignancy unable to receive curative treatment. Forty hepatocellular carcinoma (HCC) patients and two intrahepatic cholangiocarcinoma (ICC) patients signed the informed consents.
Zu‐Yau Lin, Ming‐Lun Yeh, Po‐Cheng Liang, Shinn‐Cherng Chen, Chung‐Feng Huang, Jee‐Fu Huang, Chia‐Yen Dai, Ming‐Lung Yu, Wan‐Long Chuang   +8 more
wiley   +1 more source

172P Updated analysis: observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin (OX) + BV and oral FU/OX + BV [PDF]

, 2015
Yoshito Komatsu, Satoshi Yuki, Hiroshi Nakatsumi, Kentaro Sawada, Kazuteru Hatanaka, Takashi Kato, T. Meguro, Michio Nakamura, Ichiro Iwanaga, Minoru Uebayashi, M. Tateyama, K. Eto, Masatoshi Kudo, K. Kato, Hiroyuki Okuda, Susumu Sogabe, T. Miyagishima, Kencho Miyashita, Naoya Sakamoto, Yuh Sakata   +19 more
openalex   +1 more source

Bevacizumab for the early clinical progression of diffuse intrinsic pontine glioma [PDF]

, 2023
Mamoru Honda, Kohei Fukuoka, Yutaka Tanami, Jun Kurihara, Katsuyoshi Koh   +4 more
openalex   +1 more source

Prognostic Value of the C‐PLAN Index in Advanced Esophageal Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT This study evaluated the prognostic value of the C‐PLAN index in advanced esophageal squamous cell carcinoma (ESCC) patients receiving immune checkpoint inhibitor (ICI) therapy. A retrospective analysis of 241 eligible patients treated during February 2020 to January 2023 was conducted.
Yi Zhou, Li‐Hua Yang, Jing Tang, Yuan‐Ming Li, Ping Zhao, Zan Li   +5 more
wiley   +1 more source